why choose us

First received: January 06, 2023

Clinical Trial: IMM60 and Pembrolizumab in Melanoma and NSCLC

Study Status: Completed

Recruit Status: RECRUITING

Condition: Non-small Cell Lung Cancer

Study Type: INTERVENTIONAL


Official Title: IMPORT-201: A Phase 1 First-in-Human Dose Finding/Randomized Phase 2 Study of IMM60 and Pembrolizumab for Advanced Melanoma and Metastatic NSCLC

Brief Summary: The goal of this clinical trial is to learn about IMM60 with or without pembrolizumab in participants with advanced melanoma or non-small cell lung cancer.There are two phases:Phase 1: This phase is designed to learn about the safety of IMM60 with or without pembrolizumab and to find a safe dose to test in Phase 2.Phase 2: This phase is designed to learn whether IMM60 + pembrolizumab improves progression-free survival at 12 months compared to pembrolizumab alone in participants with non-small cell lung cancer.

Read more